AngioDynamics (AngioDynamics) Change In Receivables : $0.3 Mil (TTM As of Feb. 2024)

View and export this data going back to 2004. Start your Free Trial

What is AngioDynamics Change In Receivables?

AngioDynamics's change in receivables for the quarter that ended in Feb. 2024 was $1.7 Mil. It means AngioDynamics's Accounts Receivable declined by $1.7 Mil from Nov. 2023 to Feb. 2024 .

AngioDynamics's change in receivables for the fiscal year that ended in May. 2023 was $-1.3 Mil. It means AngioDynamics's Accounts Receivable increased by $1.3 Mil from May. 2022 to May. 2023 .

AngioDynamics's Accounts Receivable for the quarter that ended in Feb. 2024 was $49.5 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. AngioDynamics's Days Sales Outstanding for the three months ended in Feb. 2024 was 60.05.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. AngioDynamics's liquidation value for the three months ended in Feb. 2024 was $38.4 Mil.

AngioDynamics Change In Receivables Historical Data

The historical data trend for AngioDynamics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioDynamics Change In Receivables Chart

AngioDynamics Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

Change In Receivables

Get a 7-Day Free Trial

-3.18

11.92

-4.16

-17.15

-1.30

AngioDynamics Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Change In Receivables	Get a 7-Day Free Trial															1.78	-2.06	3.16	-2.48	1.67

AngioDynamics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.3 Mil.

AngioDynamics (NAS:ANGO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

AngioDynamics's Days Sales Outstanding for the quarter that ended in Feb. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	49.475	/	75.182	*	91
=	60.05

2. In Ben Graham's calculation of liquidation value, AngioDynamics's accounts receivable are only considered to be worth 75% of book value:

AngioDynamics's liquidation value for the quarter that ended in Feb. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	78.451	-	106.144	+	0.75 * 49.475	+	0.5 * 58.068
=	38.4

AngioDynamics Change In Receivables Related Terms

Thank you for viewing the detailed overview of AngioDynamics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

AngioDynamics (AngioDynamics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AngioDynamics Inc (NAS:ANGO) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

UG2:Germany

Address

14 Plaza Drive, Latham, NY, USA, 12110

Website

https://www.angiodynamics.com

AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. It generates maximum revenue from Endovascular Therapies. Geographically, the company derives a majority of its revenue from the United States.

Executives

Lorinda Burgess	director	22 WEST FRONTAG ROAD, NORTHBROOK IL 60093
Karen A Licitra	director	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Michael E Tarnoff	director	C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Scott Centea	officer: SVP/GM, VIT	C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Dave Helsel	officer: SVP Global Operations and R&D	400 WOOD ROAD, BRAINTREE MA 02184
Laura Piccinini	officer: SVP International	C/O ANGIODYNAMICS INC., 14 PLAZA DRIVE, LATHAM NY 12110
Stephen A Trowbridge	officer: SVP and General Counsel	14 PLAZA DRIVE, LATHAM NY 120110
James C Clemmer	director, officer: President and CEO	COVIDIEN PLC, 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Wesley Johnson	director
Chad Thomas Campbell	officer: SVP/GM, Vascular Access	140 POKANOKET PATH, WRENTHAM MA 02093
Warren Jr Nighan	officer: SVP Quality and Regulatory	ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Richard C Rosenzweig	officer: SVP and General Counsel	C/O DENTSPLY SIRONA INC., 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kevin J Gould	director	247 WASHINGTON STREET, DUXBURY MA 02332
Brent J. Boucher	officer: SVP and GM of Oncology	14 PLAZA DRIVE, LATHAM NY 12110
Michael Greiner	officer: EVP and CFO	C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421